In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii

被引：0
作者：
Wentao Ni
Yifan Wang
Xinqian Ma
Yukun He
Jin Zhao
Jie Guan
Yanjun Li
Zhancheng Gao
机构：
[1] Peking University People’s Hospital,Department of Pulmonary and Critical Care Medicine
[2] Chinese People’s Liberation Army,Department of Respiratory Diseases, Air Force Medical Center
[3] Peking University First Hospital,Clinical Laboratory
[4] The Sixth Medical Center of PLA General Hospital,Clinical Laboratory
来源：
European Journal of Clinical Microbiology & Infectious Diseases | 2022年 / 41卷
关键词：
Cefiderocol; Combination therapy; Carbapenem-resistant ; Tigecycline; Colistin; Meropenem;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
We investigated activities of cefiderocol combination therapy against carbapenem-resistant Acinetobacter baumannii (CR-AB). A total of 123 clinical isolates of CR-AB, including 44 cefiderocol-resistant isolates were tested. Cefiderocol functioned synergistically with tigecycline in most cefiderocol-susceptible isolates (84.8%, 67/79), but not with colistin or meropenem by checkerboard method. Cefiderocol functioned synergistically with tigecycline, colistin, and meropenem in 90.9% (40/44), 47.7% (21/44), and 79.5% (35/44) cefiderocol-resistant isolates, respectively. The time-kill assay and the in vivo Galleria mellonella model confirmed these observations. In summary, cefiderocol combined with tigecycline showed synergistic effects against both cefiderocol-susceptible and -resistant CR-AB, suggesting a potentially valuable combination regimen.
引用
收藏
页码：1451 / 1457
页数：6
相关论文
共 63 条
[1]  
O'Donnell JN(2021)treatment of patients with serious infections due to carbapenem-resistant acinetobacter baumannii: how viable are the current options? Pharmacotherapy 41 762-80
[2]  
Putra V(2018)discovery, research, and development of new antibiotics: the who priority list of antibiotic-resistant bacteria and tuberculosis Lancet infect dis 18 318-27
[3]  
Lodise TP(2022)cefiderocol: a new cephalosporin stratagem against multidrug-resistant gram-negative bacteria Clin infect dis 74 1303-12
[4]  
Tacconelli E(2018)cefiderocol (s-649266), a new siderophore cephalosporin exhibiting potent activities against pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship Eur J Med Chem 155 847-68
[5]  
Carrara E(2022)cefiderocol for the treatment of multidrug-resistant gram-negative bacteria: a systematic review of currently available evidence Front Pharmacol 13 896971-40
[6]  
Savoldi A(2021)efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (credible-cr): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial Lancet Infect Dis 21 226-70
[7]  
Ong'uti S(2021)cefiderocol: an overview of its in-vitro and in-vivo activity and underlying resistant mechanisms Front Med (lausanne) 8 741940-114
[8]  
Czech M(2022)susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, gram-negative bacteria Ann Transl Med 10 261-47
[9]  
Robilotti E(2012)combination therapy for treatment of infections with gram-negative bacteria Clin Microbiol Rev 25 450-105
[10]  
Holubar M(2022)infectious diseases society of america guidance on the treatment of ampc β-lactamase-producing enterobacterales, carbapenem-resistant acinetobacter baumannii, and stenotrophomonas maltophilia infections Clin Infect Dis 74 2089-71
1234567